Health Care • Biotechnology: Commercial Physical & Biological Resarch
$359.41 ▼ -16.69
(-4.44%)
MKT CAP: $17.95B • VOL: 1.50M
52W L $146 52W H $380
CRL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-27 | FY 2024
FILED 2024-12-28 | FY 2023
FILED 2023-12-30 |
|---|---|---|---|
| Revenue (Total Sales) | $4.02B | $4.05B | $4.13B |
| YoY Revenue Growth % | -0.9% | -1.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $25.2M | $227.3M | $617.3M |
| Operating Margin % | 0.6% | 5.6% | 14.9% |
| Net Income (GAAP) | -$144.3M | $22.2M | $474.6M |
| EBITDA (Normalized) | $169.7M | $373.1M | $765.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $737.6M | $734.6M | $683.9M |
| Capital Expenditures (CapEx) | $180.7M | $182.2M | $185.8M |
| Free Cash Flow (FCF) | $557.0M | $552.3M | $498.1M |
| FCF Margin % | 13.9% | 13.6% | 12.1% |
| Return on Invested Capital (ROIC %) | 0.4% | 3.5% | 8.2% |
| Cash & Short-Term Equivalents | $213.8M | $194.6M | — |
| Total Debt (Short + Long Term) | $1.77B | $1.81B | $2.31B |
| Total Stockholders' Equity | $3.16B | $3.46B | $4.74B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRL.